The United States Food and Drug Administration (FDA) has approved France-based Sanofi's Fluzone High-Dose Quadrivalent (Influenza Vaccine) intended for use in adults, aged 65 and over, it was reported yesterday.
The United States regulator approved the trivalent influenza vaccine in 2009, for the two influenza A strains and one influenza B strain.
The vaccine's quadrivalent formulation includes an additional influenza B strain. Following the approval of its supplemental biologics license application, the product can be used in the United States to protect older people from influenza disease caused by influenza A and B strains present in the vaccine. The product's approval was driven by the results of a phase three immunogenicity and safety study.
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
GSK's meningitis vaccine candidate accepted for FDA review
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study